SingleMetabolic & Weight

VK2735 10mg

Investigational dual GIP and GLP-1 receptor agonist studied for significant dose-dependent weight loss and metabolic regulation.

Mechanism

Simultaneously engages GLP-1 and GIP incretin receptors to slow gastric emptying, suppress central appetite signals via AgRP neuron inhibition, and modulate glucose homeostasis.

Dosing

Research protocols document an initial weekly subcutaneous administration of 2.5 mg.

Reconstitution

Add 2.0 mL of bacteriostatic water to achieve a final working concentration of 5 mg/mL (5,000 mcg/mL).

Storage

Store lyophilized powder protected from light at 2–8°C or frozen, and maintain reconstituted solutions at 2–8°C for up to 28 days.

Mix & measure VK2735 10mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure VK2735 10mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration5.00mg/mL

Draw volume0.500mL

On the syringe50.0units

Total doses in vial: 4.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4	2.5 mg (1× weekly)	50 units (0.50 mL)
Weeks 5–8	5 mg (1× weekly)	100 units (1.00 mL)
Weeks 9–12	7.5 mg (1× weekly)	150 units (1.50 mL)
Week 13+	10 mg (1× weekly)	200 units (2.00 mL)

Reconstitution Steps

1
Sanitize the stoppers of both the lyophilized peptide vial and the bacteriostatic water vial using sterile alcohol prep pads.
2
Draw precisely 2.0 mL of bacteriostatic water into a sterile syringe.
3
Direct the needle tip toward the inner glass wall of the peptide vial, allowing the diluent to trickle slowly over the powder.
4
Swirl the container in a gentle circular motion until completely transparent without shaking vigorously.
5
Date the vial and immediately place into refrigerated storage at 2–8°C.

Supplies Needed

Peptide Vial

Lyophilized active research peptide (10 mg)

Insulin Syringes (U-100)

Calibrated subcutaneous delivery and micro-volume extraction

Bacteriostatic Water

Sterile dilution preserving compound integrity across multi-dose cycles

Alcohol Swabs

Aseptic preparation of rubber stoppers and injection interfaces

Why researchers study it

Dose-dependent weight loss exploration

Dual GIP and GLP-1 receptor agonism comparison

Hypothalamic AgRP appetite regulation

Parallel evaluation of subcutaneous and oral delivery

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

VK2735 is an investigational synthetic peptide engineered as a dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Developed primarily to evaluate potent interventions in metabolic disorders and adiposity, the compound utilizes a dual-incretin pathway mirroring the physiological mechanism seen in modern multi-target metabolic therapies. By engaging both hormonal cascades simultaneously, it coordinates glycemic control and central satiety responses. In preclinical models and clinical dose-ranging trials such as the phase 2 VENTURE study, the peptide has been evaluated across once-weekly subcutaneous regimens. Investigators focus on its capacity to drive substantial, progressive weight reduction and metabolic improvements while monitoring the typical gastrointestinal adaptation profile associated with incretin-mimetic therapies. As an unapproved investigational agent, handling requires strict laboratory containment and precision measurement.